Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

IQVIA Holdings, Inc. Common Stock (NY:IQV)

164.09 -2.85 (-1.71%)
Streaming Delayed Price Updated: 2:03 PM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about IQVIA Holdings, Inc. Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022 ↗
 
Via Benzinga
Expert Ratings for IQVIA Hldgs ↗
 
Via Benzinga
News headline image
Veracyte Stock Showing Market Leadership; Earns 93 RS Rating ↗
Veracyte shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Where IQVIA Hldgs Stands With Analysts ↗
 
Via Benzinga
Analyst Ratings for IQVIA Hldgs ↗
 
Via Benzinga
8 Analysts Have This to Say About IQVIA Hldgs ↗
IQVIA Hldgs (NYSE:IQV) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
7 Analysts Have This to Say About IQVIA Hldgs ↗
Analysts have provided the following ratings for IQVIA Hldgs (NYSE:IQV) within the last quarter: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Target To Rally 29%? Plus This Analyst Predicts $245 For IQVIA Holdings ↗
Piper Sandler boosted the price target on Target Corporation (NYSE: TGT) from $190 to $200. Target shares fell 13.1% to close at $155.47 on Wednesday. 
Via Benzinga
News headline image
Expert Ratings for IQVIA Hldgs ↗
Analysts have provided the following ratings for IQVIA Hldgs (NYSE:IQV) within the last quarter: 
Via Benzinga
News headline image
6 Analysts Have This to Say About IQVIA Hldgs ↗
Analysts have provided the following ratings for IQVIA Hldgs (NYSE:IQV) within the last quarter: 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About IQVIA Hldgs ↗
Within the last quarter, IQVIA Hldgs (NYSE:IQV) has observed the following analyst ratings: 
Via Benzinga
News headline image
IQVIA and Clalit Health Services partner to advance research by launching the first Prime Site in Israel
From IQVIA
Via Business Wire
News headline image
General Electric To Rally Around 14%? Here Are 5 Other Price Target Changes For Thursday ↗
  Morgan Stanley raised General Electric Company (NYSE: GE) price target from $85 to $88. Morgan Stanley analyst Joshua Pokrzywinski maintained the stock with an Overweight rating. GE shares rose 2.2%... 
Via Benzinga
News headline image
IQVIA: Q3 Earnings Insights ↗
IQVIA Hldgs (NYSE:IQV) reported its Q3 earnings results on Wednesday, October 26, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings IQVIA Hldgs beat estimated... 
Via Benzinga
News headline image
IQVIA Reports Third-Quarter 2022 Results
From IQVIA Holdings Inc.
Via Business Wire
News headline image
5 Analysts Have This to Say About IQVIA Hldgs ↗
Within the last quarter, IQVIA Hldgs (NYSE:IQV) has observed the following analyst ratings: 
Via Benzinga
News headline image
Medpace Earnings Are 'Almost Unbelievable'; MEDP Stock Flies ↗
Medpace earnings soared in Q3 as weakness in contract awards turned to strength, sending MEDP stock surging. 
Via Investor's Business Daily
News headline image
Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy? ↗
Biosimilars are bringing down prescription drug costs without sacrificing quality. 
Via The Motley Fool
News headline image
IQVIA CFO Ron Bruehlman to Speak at Credit Suisse Annual Healthcare Conference on November 8, 2022
From IQVIA Holdings Inc.
Via Business Wire
News headline image
Q² Solutions Launches Innovative Self-Collection Safety Lab Panel in Collaboration With Tasso
From IQVIA
Via Business Wire
News headline image
Tesla To $370? Plus HC Wainwright Slashes PT On This Stock By 67% ↗
HC Wainwright & Co. cut KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) price target from $48 to $16. KalVista Pharmaceuticals shares fell 1.8% to $5.06 in pre-market trading. 
Via Benzinga
News headline image
IQVIA to Announce Third-Quarter 2022 Results on October 26, 2022
From IQVIA Holdings Inc.
Via Business Wire
News headline image
IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation
From IQVIA
Via Business Wire
News headline image
New IQVIA Study Demonstrates Cost and Time Savings of Decentralized Trials
From IQVIA
Via Business Wire
News headline image
IQVIA CEO Ari Bousbib to Speak at Baird Global Healthcare Conference on September 14, 2022
From IQVIA
Via Business Wire
News headline image
IQVIA CFO Ron Bruehlman to Speak at Morgan Stanley Annual Global Healthcare Conference on September 13, 2022
From IQVIA Holdings Inc.
Via Business Wire
News headline image
IQVIA Wins Snowflake’s “Marketplace Healthcare and Life Sciences Partner of the Year” Award
From IQVIA
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Peering Into IQVIA's Recent Short Interest ↗
IQVIA Hldgs (NYSE:IQV) short percent of float has fallen 20.35% since its last report. The company recently reported that it has 1.67 million shares sold short, which... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.